西藏易明西雅医药科技股份有限公司 2025年度业绩预告

Group 1 - The company expects a positive net profit for the year 2025, with an increase of over 50% compared to the previous year [1] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] - The preliminary estimate of non-recurring gains and losses is expected to impact net profit by approximately 43 million yuan, primarily from government subsidies and compensation from Bositai [1] Group 2 - The company has focused on developing its self-produced products, particularly the core product Miglitol tablets, which has led to increased sales and overall profit growth [1] - There are no significant disagreements between the company and the auditing accounting firm regarding the performance forecast [1]